What the HHT?
A blog for the HHT community
Front Page Announcements
Press Release: Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of HHT
Diagonal Therapeutics — who has raised $128 million in Series A funding to support their sole project, a curative HHT therapy — today issued the below press release outlining new research demonstrating the significant healthcare cost impact of HHT. This data will be significantly important in advocating for funding for HHT, as well as attracting…
Read MorePress Release: Vaderis Receives FDA Fast Track Designation for Treatment of HHT
The below press release was issued Monday, Nov. 18 by Vaderis Therapeutic, and is substantial news for our community. Cure HHT has worked hand-in-hand with leadership at Vaderis throughout this process — helping encourage them to focus on HHT, informing trial design, and supporting recruitment. We are the catalyst that drives progress for HHT, and this news…
Read MoreCure HHT to Host 15th HHT International Scientific Conference
One of the most meaningful ways Cure HHT works to advance research and science is through our HHT International Scientific Conference. Every two years, the world’s brightest minds in HHT medicine and science convene at our meeting to discuss the latest research. These events fuel collaboration between physicians and scientists, helping to fast track the…
Read MorePress Release: Cure HHT Plays Key Role in First Successful HHT Trial
For more than 30 years, Cure HHT has helped to expand the research and medical community focusing on HHT.
We’re thrilled to share some important news from the world of HHT research.
The National Institutes of Health-sponsored PATH trial is complete, the results are in, and it marks an important step forward for HHT treatment and care. This trial was the first positive, large-scale randomized trial for an HHT therapeutic. This study tested the use of the cancer drug pomalidomide in treatment of HHT-related bleeding — and researchers saw very promising results. The data was strong enough that the trial ended early!
But the news gets even better: Now, the full results of the study are published in the New England Journal of Medicine (you can read it here) — one of the most prestigious medical publications in the world, read by more than one million physicians every week. This is a huge win for HHT Awareness, as this publication puts HHT in the spotlight of the medical community.
At Cure HHT, we are the catalyst for driving HHT science forward. We’re proud to have played an important role in advocating for the funding necessary to run this study, and in recruitment to ensure its success.
Read our full press release here and learn more about this milestone below.
Read MoreA Monumental $128 Million Step Forward for HHT Research
Today is a monumental day for HHT. The new biotechnology company, Diagonal Therapeutics, officially launched and we wanted to share more about why this is news you simply can’t miss!
In short, Diagonal’s lead program is focused on developing an innovative treatment not just to alleviate the symptoms of HHT – but using antibodies to reverse the formation of vascular malformations altogether. That’s right, there is now a biotechnology company, backed by $128 million in Series A financing, focused entirely on a curative HHT therapy.
For months, Cure HHT has been collaborating with Diagonal’s management team to help make this day a reality. We have connected them to leading HHT scientists to help them further develop their program, and have spent countless hours meeting with venture capital firms to educate them on the burden of this disease and help Diagonal secure funding to launch.
Read More